JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Elenco Azioni・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

21.95 -2.4

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.69

Massimo

Metriche Chiave
By Trading Economics
Entrata	202M 274M
Vendite	5.4M 284M
P/E Media del settore	9.696 67.147
Margine di Profitto	96.33
Dipendenti	796
EBITDA	-21M 26M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+40.49% upside

Dividendi
By Dow Jones
Utili prossimi	6 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-366M 3.8B
Apertura precedente	24.35
Chiusura precedente	21.95

Notizie sul Sentiment di mercato

By Acuity

28%

72%

79 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

14.845 / N/A Supporto e resistenza

ACADIA Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 mag 2026, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 mag 2026, 20:40 UTC

Acquisizioni, Fusioni, Takeovers

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 mag 2026, 18:37 UTC

I principali Market Mover

Senseonic Shares Slide on Underwritten Offering Price

1 mag 2026, 16:46 UTC

I principali Market Mover

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 mag 2026, 20:42 UTC

Utili

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 mag 2026, 19:18 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 mag 2026, 19:13 UTC

Discorsi di Mercato

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 mag 2026, 18:36 UTC

Utili

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 mag 2026, 18:35 UTC

Utili

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mag 2026, 18:28 UTC

Utili

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 mag 2026, 18:27 UTC

Discorsi di Mercato

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 mag 2026, 18:14 UTC

Acquisizioni, Fusioni, Takeovers

Barclays Completes Acquisition of Best Egg

1 mag 2026, 18:04 UTC

Utili

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 mag 2026, 17:43 UTC

Discorsi di Mercato

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 mag 2026, 17:37 UTC

Discorsi di Mercato

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 mag 2026, 17:30 UTC

Discorsi di Mercato

Utili

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 mag 2026, 17:28 UTC

Discorsi di Mercato

Utili

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 mag 2026, 17:21 UTC

Discorsi di Mercato

Utili

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 mag 2026, 17:19 UTC

Discorsi di Mercato

Principali Notizie su Eventi

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 mag 2026, 16:38 UTC

Discorsi di Mercato

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 mag 2026, 16:23 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 mag 2026, 16:15 UTC

Utili

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

1 mag 2026, 16:11 UTC

Discorsi di Mercato

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

1 mag 2026, 16:04 UTC

Utili

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Confronto tra pari

Modifica del prezzo

ACADIA Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

40.49% in crescita

Previsioni per 12 mesi

Media 31.54 USD 40.49%

Alto 40 USD

Basso 23 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ACADIA Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

15 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 15 che hanno fornito valutazioni azionarie a ACADIA Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

14.845 / N/ASupporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

79 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.